DigestRedComo funciona
Red
/
Empresas
Te
No verificado

Teva Pharmaceutical Industries Ltd

Sobre qué escribimos

Anuncios brevesFarmacéuticaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

53 Comunicados de prensa

Ver todos los comunicados de prensa
30/05/2025
Farmacéutica
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0
30/05/2025
Farmacéutica
Medicina Salud Bienestar
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0
29/05/2025
Farmacéutica
Medicina Salud Bienestar
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0
27/05/2025
Farmacéutica
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0
27/05/2025
Farmacéutica
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0
27/05/2025
Farmacéutica
Medicina Salud Bienestar
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0
22/05/2025
Farmacéutica
Finanzas
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0
20/05/2025
Farmacéutica
Finanzas
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0
20/05/2025
Farmacéutica
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0
19/05/2025
Farmacéutica
Finanzas
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1,00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0